Standout Papers

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibril... 2001 2026 2009 2017 6.5k
  1. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (2011)
    Manesh R. Patel, Kenneth W. Mahaffey et al. New England Journal of Medicine
  2. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study (2001)
    Shamir R. Mehta, Salim Yusuf et al. The Lancet
  3. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome (2011)
    Jessica L. Mega, Eugene Braunwald et al. New England Journal of Medicine
  4. A Validated Prediction Model for All Forms of Acute Coronary Syndrome (2004)
    Kim A. Eagle, Michael J. Lim et al. JAMA
  5. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) (2006)
    Keith A.A. Fox, Omar Dabbous et al. BMJ
  6. A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease (1997)
    Marc J. Cohen, Christine Demers et al. New England Journal of Medicine
  7. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes (2006)
    John W. Eikelboom, Shamir R. Mehta et al. Circulation
  8. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes (2004)
    James A. de Lemos, Michael A. Blazing et al. JAMA
  9. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI (2016)
    C. Michael Gibson, Roxana Mehran et al. New England Journal of Medicine
  10. Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure (1998)
    James Nolan, Phillip D Batin et al. Circulation
  11. Vorapaxar in the Secondary Prevention of Atherothrombotic Events (2012)
    David A. Morrow, Eugene Braunwald et al. New England Journal of Medicine
  12. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial (2013)
    Nikhil Joshi, Alex Vesey et al. The Lancet
  13. Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006 (2007)
    Keith A.A. Fox, Philippe Gabríel Steg et al. JAMA
  14. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome (2004)
    Keith A.A. Fox, Shamir R. Mehta et al. Circulation
  15. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial (2002)
    Keith A.A. Fox, P A Poole-Wilson et al. The Lancet
  16. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes (2009)
    Shamir R. Mehta, Christopher B. Granger et al. New England Journal of Medicine
  17. International Day for the Evaluation of Abdominal Obesity (IDEA) (2007)
    Beverley Balkau, John Deanfield et al. Circulation
  18. Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes (2005)
    Shamir R. Mehta, Christopher P. Cannon et al. JAMA
  19. Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes (2010)
    Clara K Chow, Sanjit S. Jolly et al. Circulation
  20. Color Doppler Myocardial Imaging: A New Technique for the Assessment of Myocardial function (1994)
    George R. Sutherland, Michael J. Stewart et al. Journal of the American Society of Echocardiography
  21. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment (2011)
    Keith A.A. Fox, Jonathan P. Piccini et al. European Heart Journal
  22. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (2014)
    Jonathan L. Halperin, Graeme J. Hankey et al. Circulation
  23. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study (2015)
    Anoop Shah, Megan E. Griffiths et al. BMJ
  24. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease (2018)
    Sonia S. Anand, François Caron et al. Journal of the American College of Cardiology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 143 standout
Sub-graph 1 of 17

Citing Papers

Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction
2024 Standout
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
2020 Standout
55 intermediate papers

Works of Keith A.A. Fox being referenced

Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation
2012
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
and 59 more

Author Peers

Author Last Decade Papers Cites
Keith A.A. Fox 46242 15084 10760 11912 808 57.9k
Lars Wallentin 47953 13944 7240 14817 733 57.5k
Elliott M. Antman 46958 16447 10589 9335 515 57.8k
Christopher B. Granger 48225 13453 9696 7147 833 62.0k
Harvey D. White 43840 21177 13505 5684 705 56.2k
Frans Van de Werf 30131 12126 9820 4553 746 39.2k
Eugene Braunwald 41820 18050 12184 4435 444 56.1k
Sabina A. Murphy 29083 17306 6173 5729 482 42.0k
Philippe Gabríel Steg 54884 29325 9926 9318 1.1k 74.8k
Bernard J. Gersh 60179 18709 13371 4974 1.1k 74.3k
Eugene Braunwald 49596 29906 11807 7900 687 75.0k

All Works

Loading papers...

Rankless by CCL
2026